Navigation Links
Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
Date:4/21/2011

ANN ARBOR, MICH. -- A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

Almost 1,000 patients who had advanced, hormone-refractory prostate cancer were given up to 36 weeks of chemotherapy with docetaxel and prednisone. These patients were randomized so that one half got an additional pill with a dose of atrasentan while the other half got a placebo pill. Patients who completed their chemotherapy and showed no progression of the disease were given the option of continuing the additional blinded pill (atrasentan or placebo).

The study's DSMC evaluated a planned interim analysis of trial data and determined the evidence indicating no benefit from the drug was strong enough to close the study early rather than waiting another 18 months as was originally planned. The DSMC did not find evidence that the drug was harming patients.

New patient enrollment to the study stopped in April 2010 and few patients continue to take the study pill. Patients still taking study medication should speak to their doctor about stopping safely and what to do with their remaining pills. Treatment assignment is being unblinded, so patients can learn from their study doctor whether they took atrasentan or a placebo.

The study ("S0421: Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer") was supported by the National Cancer Institute (NCI) and was conducted by SWOG (formerly the Southwest Oncology Group) with the participation of several other NCI cooperative groups.

Atrasentan for the trial was provided under an agreement with Abbott Laboratories and was distri
'/>"/>

Contact: Frank DeSanto
fdesanto@umich.edu
734-998-0114
University of Michigan Health System
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. NHGRI charts course for the next phase of genomics research
2. Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
3. Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
4. Phase I trial indicates ponatinib may thwart most resistant CML
5. Assessing positive outcomes of phase III trials
6. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
7. Nutrition rating enhancing front-of-package nutrition rating systems and symbols: Phase 1
8. New Phase II study shows first-line promise of lung cancer drug PF-299
9. Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer
10. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
11. Front-of-package symbols and systems: IOM phase 1 report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... Each year, the American Gastroenterological Association (AGA) recognizes ... in gastroenterology through its esteemed recognition awards. , ... individuals who work tirelessly to advance the science ... to announce the 2013 recognition award honorees who ... tremendous contributions to our field," said Loren Laine, ...
(Date:5/18/2013)... California (PRWEB) May 18, 2013 Online watch ... be Rolex watch owners at a fraction of ... of luxury timepieces in the world, buyers are urged to ... compared to buying a Rolex watch from a brick-and-mortar store, ... owned Rolex watches priced at unbelievable rates. Although some ...
(Date:5/18/2013)... who swallow high-powered magnets often need surgery and other ... new study. The researchers, from the Louisiana State ... than 79 percent of children who swallowed very strong ... in which a tube containing a camera is inserted ... cases can be treated through observation or by pumping ...
(Date:5/18/2013)... The use of a smartphone application significantly improves ... research presented today at Digestive Disease Week (DDW). ... of the procedure, includes dietary restrictions and requires ... strict intervals. The better the preparation, the easier ... precancerous polyps in the colon. The study, which ...
(Date:5/18/2013)... May 18, 2013 In a May ... Preventive Double Mastectomy After Discovering Cancer Gene,” Fox News ... procedure upon learning that she carried a gene that ... breast cancer and a 50 percent risk of ovarian ... up on May 16, 2013 with a blog post ...
Breaking Medicine News(10 mins):Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 2Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 3Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 4Health News:AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards 5Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New smartphone application improves colonoscopy preparation 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2
... ayurveda practitioners should get licences to practice this ancient ... ,Lakshmi C. Mishra, director of the Ayurvedic Health ... Board of Physicians to introduce an official licensing programme, ... ,The ayurveda system of medicine is based on the ...
... face a risk of dementia, which is a disorder of ... changes. ,Every year, about 23,000 US women are ... disease. To reduce the risk of this disease surgeons often ... Walter Rocca at Mayo Clinic studied 2,511 women who had ...
... list is growing day by day, the New South Wales (NSW) ... queue//. ,It has decided to allocate to more money ... help cut elective surgery waiting lists. ,The Hunter New ... boost of $500,000 each. ,This would help them to ...
... The HIV Sentinel Surveillance data for 2005 shows the prevalence ... in the state.// According to the latest study that was ... that the prevalence among antenatal women has fallen to 0.5 ... comprising 24 district headquarters hospitals, 29 first referral units, 5 ...
... The Union Finance Minister P. Chidambaram said that the inflation rate ... remain under control.// ,He said that various steps are ... happy it is below four percent now. Anything under four percent ... , Asked whether the government had any benchmark to contain the ...
... and a veteran Orissa Congress leader died after a brief ... after his recent surgery and since then he was not ... and died before his family doctor could reach his residence, ... sons and four daughters. Mohapatra was elected to the Orissa ...
Cached Medicine News:Health News:Proposal to license Ayurveda Practitioners in the US 2
(Date:5/17/2013)... -- Boston Scientific Corporation (NYSE: BSX ) is ... May 21-24 in Paris . ... and diversified set of data this year at EuroPCR," ... chief medical officer, Boston Scientific.  "The primary endpoint results ... PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... May 16, 2013  PTC Therapeutics, Inc., today announced ... S-1 with the U.S. Securities and Exchange Commission ("SEC") ... common stock. The number of shares to be offered ... been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... as joint book-running managers for the offering. Cowen and ...
(Date:5/16/2013)... SYDNEY , May 16, 2013  HeartWare ... a leading innovator of less invasive, miniaturized circulatory support technologies ... announced that CEO Doug Godshall is ... at 11:00 a.m. EDT on Monday, May 20, 2013.  The ... New York Hotel. A live webcast of the ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... Francisco, Inc. announced today that Michael Buckley, Ph.D., has ... Dr. Buckley will be responsible for directing all aspects ... for production of therapeutic antibody candidates at Takeda,s antibody ... "Mike brings over 20 years of experience in the ...
... Aprima Medical Software (originally iMedica), a ... management (PM) systems for medical practices, today announced that ... practice located in Bend, Oregon. Following years of ... after a positive experience with Aprima,s "Take-A-Tablet" program, a ...
Cached Medicine Technology:Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences 2Aprima's EHR Helps Bend Urology Associates Improve Efficiency, Workflow 2Aprima's EHR Helps Bend Urology Associates Improve Efficiency, Workflow 3
Cruciate retaining, posterior stabilized and constrained components....
The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
... Solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
...
Medicine Products: